The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Profound Medical (PROF) shares soared 8.2% in the last trading session to close at $7.37. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

View Profound Medical Corp PROF stock quote prices, financial information, real-time forecasts, and company news from CNN.

Profound Medical (NASDAQ:PROF) is set to give its latest quarterly earnings report on Thursday, 2026-03-05. Here's what investors need to know before the announcement. Analysts estimate that Profound ...

) has been revised to $8.49 / share. This is a decrease of 26.77% from the prior estimate of $11.60 dated February 23, 2026. The price target is an average of many targets provided by analysts. The ...

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

The latest price target for Profound Medical (NASDAQ:PROF) was reported by Lake Street on April 23, 2025. The analyst firm set a price target for $11.00 expecting PROF to rise to within 12 months (a ...

Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the ...

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million. 67% were treated for prostate cancer only, 17% were hybrid patients suffering from both ...